This document provides a summary of pediatric oncology phase I and II clinical trials being conducted at Doernbecher Children's Hospital. It lists the treatment groups, study identification numbers, phases, study names, and principal investigators and coordinators for trials focusing on brain tumors, solid tumors, leukemia, and other conditions. Over 20 active studies are described.
This document summarizes research on developing antibodies to target misfolded proteins involved in Alzheimer's disease like amyloid beta peptides. Key findings include:
1) Researchers designed "Gammabodies" that graft short peptide motifs from amyloid beta onto antibody structures to target specific conformations of amyloid beta oligomers and fibrils.
2) Gammabody antibodies were shown to competitively bind amyloid beta conformers, recognizing the same peptide segments as the misfolded protein targets.
3) In cell culture experiments, selected Gammabodies inhibited the toxicity of amyloid beta oligomers and fibrils, demonstrating their potential for neutralizing the pathological forms of these proteins.
The document summarizes research on developing antibodies called "Gammabodies" to target misfolded proteins involved in Alzheimer's disease like amyloid beta (Aβ). Gammabodies are designed to recognize different aggregated conformations of Aβ, including oligomers and fibrils, by grafting specific Aβ peptide motifs onto antibody structures. Studies showed Gammabodies can competitively bind to Aβ conformers and neutralize the toxicity of oligomers and fibrils in cell cultures. The approach aims to produce antibodies that can target the various pathological forms of Aβ protein associated with Alzheimer's disease.
Navigating the FDA: Getting to Market – CVG Second Thursday, 3/14/13Paige Rasid
The document discusses how cancer biomarker discovery has evolved from focusing on single biomarkers identified through laboratory findings and requiring many years of development, to now interrogating entire cancer genomes through sequencing. This allows the identification of many markers from few samples. Structural mutations in cancer genomes are analyzed, finding higher-level organization to private mutations. A fusion gene indicator of genomic instability in breast cancer is identified in 30% of cases. Genomic organization shows chromosomes can generate "cancer gene cassettes" and the germline affects therapeutic outcome. Focus is shifting to systems oncogenomics and structural mutations in cancer.
1. Hematopoietic stem cell transplantation (HSCT) can provide long-term remission for some CML patients, but it carries risks of mortality and morbidity.
2. HSCT is best considered after failure of tyrosine kinase inhibitor (TKI) therapy or for accelerated/blast phase disease.
3. Directly after diagnosis, HSCT may be too risky due to transplant-related risks outweighing potential benefits. In blast crisis phase, HSCT may be too late due to disease progression.
The document outlines the BIOSAP study which aims to characterize the neuropsychological and endocrine consequences of blast traumatic brain injury by comparing it to civilian traumatic brain injury and assessing for a specific pattern of white matter damage using MRI. The study will recruit moderate to severe blast injured soldiers from the ADMEM database and DMRC Headley Court to undergo neuropsychological testing, structural and functional MRI, and endocrine assessments at Birmingham hospitals.
The document contains several clinical case summaries presented as questions with multiple choice answers. It discusses cases involving issues like knee pain, respiratory acidosis, Huntington's disease, lupus, lower back pain, and hydronephrosis during pregnancy. For each case, a question is asked to test the reader's knowledge and the most appropriate answer is provided.
This document summarizes several Phase I and Phase II clinical trials being conducted at Doernbecher Children's Hospital for pediatric oncology patients. It lists the treatment groups, study names, identification numbers, phases, site investigators, and contact information for various brain tumor, solid tumor, and leukemia studies. The studies are investigating new drug therapies and combinations for children with recurrent, refractory, or newly diagnosed cancers like ependymoma, gliomas, medulloblastoma, and others.
This document outlines the need for specialized training of healthcare professionals in adolescent and young adult (AYA) oncology. It notes that cancers often manifest differently and have varying treatment responses in the AYA population compared to children and older adults. Additionally, AYAs face unique developmental and psychosocial challenges due to cancer. The LIVESTRONG Young Adult Alliance assembled experts who recommend training in three areas: AYA-specific medical knowledge; care delivery tailored to AYAs; and competency in applying practical AYA knowledge. This training seeks to address gaps not covered in traditional pediatric and adult oncology programs to better serve AYA patients with cancer.
This document summarizes research on developing antibodies to target misfolded proteins involved in Alzheimer's disease like amyloid beta peptides. Key findings include:
1) Researchers designed "Gammabodies" that graft short peptide motifs from amyloid beta onto antibody structures to target specific conformations of amyloid beta oligomers and fibrils.
2) Gammabody antibodies were shown to competitively bind amyloid beta conformers, recognizing the same peptide segments as the misfolded protein targets.
3) In cell culture experiments, selected Gammabodies inhibited the toxicity of amyloid beta oligomers and fibrils, demonstrating their potential for neutralizing the pathological forms of these proteins.
The document summarizes research on developing antibodies called "Gammabodies" to target misfolded proteins involved in Alzheimer's disease like amyloid beta (Aβ). Gammabodies are designed to recognize different aggregated conformations of Aβ, including oligomers and fibrils, by grafting specific Aβ peptide motifs onto antibody structures. Studies showed Gammabodies can competitively bind to Aβ conformers and neutralize the toxicity of oligomers and fibrils in cell cultures. The approach aims to produce antibodies that can target the various pathological forms of Aβ protein associated with Alzheimer's disease.
Navigating the FDA: Getting to Market – CVG Second Thursday, 3/14/13Paige Rasid
The document discusses how cancer biomarker discovery has evolved from focusing on single biomarkers identified through laboratory findings and requiring many years of development, to now interrogating entire cancer genomes through sequencing. This allows the identification of many markers from few samples. Structural mutations in cancer genomes are analyzed, finding higher-level organization to private mutations. A fusion gene indicator of genomic instability in breast cancer is identified in 30% of cases. Genomic organization shows chromosomes can generate "cancer gene cassettes" and the germline affects therapeutic outcome. Focus is shifting to systems oncogenomics and structural mutations in cancer.
1. Hematopoietic stem cell transplantation (HSCT) can provide long-term remission for some CML patients, but it carries risks of mortality and morbidity.
2. HSCT is best considered after failure of tyrosine kinase inhibitor (TKI) therapy or for accelerated/blast phase disease.
3. Directly after diagnosis, HSCT may be too risky due to transplant-related risks outweighing potential benefits. In blast crisis phase, HSCT may be too late due to disease progression.
The document outlines the BIOSAP study which aims to characterize the neuropsychological and endocrine consequences of blast traumatic brain injury by comparing it to civilian traumatic brain injury and assessing for a specific pattern of white matter damage using MRI. The study will recruit moderate to severe blast injured soldiers from the ADMEM database and DMRC Headley Court to undergo neuropsychological testing, structural and functional MRI, and endocrine assessments at Birmingham hospitals.
The document contains several clinical case summaries presented as questions with multiple choice answers. It discusses cases involving issues like knee pain, respiratory acidosis, Huntington's disease, lupus, lower back pain, and hydronephrosis during pregnancy. For each case, a question is asked to test the reader's knowledge and the most appropriate answer is provided.
This document summarizes several Phase I and Phase II clinical trials being conducted at Doernbecher Children's Hospital for pediatric oncology patients. It lists the treatment groups, study names, identification numbers, phases, site investigators, and contact information for various brain tumor, solid tumor, and leukemia studies. The studies are investigating new drug therapies and combinations for children with recurrent, refractory, or newly diagnosed cancers like ependymoma, gliomas, medulloblastoma, and others.
This document outlines the need for specialized training of healthcare professionals in adolescent and young adult (AYA) oncology. It notes that cancers often manifest differently and have varying treatment responses in the AYA population compared to children and older adults. Additionally, AYAs face unique developmental and psychosocial challenges due to cancer. The LIVESTRONG Young Adult Alliance assembled experts who recommend training in three areas: AYA-specific medical knowledge; care delivery tailored to AYAs; and competency in applying practical AYA knowledge. This training seeks to address gaps not covered in traditional pediatric and adult oncology programs to better serve AYA patients with cancer.
This document recognizes and honors individuals from the OHSU Knight Cancer Institute for their contributions in areas like clinical care, research, outreach, diagnostics, and informed consent. It provides photos and names of researchers, doctors, nurses, and staff being recognized for their work in areas such as breast cancer research and care, clinical scholars, phase I clinical trials, community outreach, prostate cancer research, diagnostic testing, and developing an informed consent model.
The document provides an agenda for OHSU PAIN Day 2012, an event taking place on February 28th from 12pm to 6pm at the Vey Conference Center at Doernbecher Children's Hospital. The agenda includes introductions, workshops on managing pain in different populations and facial pain, presentations on drug development and opioids for chronic pain, poster sessions, and a networking social hour. Registration is free online and continuing education credits will be provided.
This grant supports research using quantitative dual-energy CT (DECT) iodine measurements to evaluate treatment response in patients with liver metastases from colon cancer undergoing chemotherapy. DECT may allow earlier detection of treatment response compared to current size-based methods. The goal is to validate intralesional iodine concentration as a biomarker for predicting and monitoring response to anti-angiogenic chemotherapy. If successful, DECT iodine quantification could help personalize chemotherapy regimens and lead to improved outcomes for these patients.
A benefit event will be held on December 8th from 6:30-8:30pm at AVA Roasteria in Beaverton, Oregon to support patient services at the OHSU Knight Cancer Institute. Attendees can enjoy wine, hors d'oeuvres and music while learning how donations make a difference for cancer patients. A "snowball effect" fundraiser will also be held where purchasing gifts between $50-$1000 will help support wellness programs, art therapy, and patient assistance.
The Knight Cancer Institute Seminar Series will host Dr. Bradley Olwin from the University of Colorado, Boulder on December 13, 2011. Dr. Olwin will present on "The Role of the Niche in Self-Renewal & Transplantation of Muscle Stem Cells". The seminar will take place from 4:00-5:00pm in the OHSU Main Hospital 8th Floor Conference Room 8B60. The presentation will discuss the potential of muscle stem cell therapies and the mechanisms governing muscle stem cell self-renewal. The seminar is open to the public and provides continuing education credits for physicians.
Carolyn Blasdel is a research nurse at The Knight Cancer Institute. A patient submitted a letter praising Carolyn for her outstanding care and dedication. When the patient developed severe abdominal pain on a trip to Portland for a clinical trial, Carolyn dropped everything to meet and help the patient, correctly diagnosing acute pancreatitis. She stayed with the patient until evening and worked late into the night to prepare for the next day, showing continued support over following days. The patient said Carolyn is a huge asset to her care team and deserves recognition for her dedication to patients.
Sierra Romesburg from the Breast Center went above and beyond her normal duties to fill a gap when the center was without a nurse for six months. She teamed up with a registered nurse to take on nurse duties like calling patients to provide reassurance about their cancer diagnosis. Sierra is very knowledgeable about breast cancer treatments from independently researching the topic. She strives to educate patients on all treatment options available and never refuses patient requests, going to great lengths to fulfill them. Her dedication and willingness to take on extra work impress her colleagues.
Survival rates for adolescents and young adults (ages 15-39) with cancer have lagged behind progress made in children and older adults over the past 20 years. While significant strides have been made recently, more work is still needed. Key challenges contributing to lower survival in this age group include differences in cancer biology, lack of clinical trial participation, health insurance barriers, and lack of psychosocial support systems tailored for their unique needs and life stages. The oncology community has started to address these issues through greater research focus on this population, improved guidelines, and programs dedicated to their care. However, broad changes are still required to improve outcomes for adolescents and young adults with cancer.
Imjai Chitapanarux is a radiation oncologist and chair of the Division of Therapeutic Radiology and Oncology at Chiang Mai University's Faculty of Medicine in Thailand. He holds an MD and leads the division of radiation oncology and oncology at one of Thailand's top medical schools.
This project describes methods for recruiting and retaining adolescent and young adult (AYA) oncology patients in psychosocial research studies at a single institution. Key methods included:
1) Monitoring clinic schedules and patient wards daily to identify eligible patients and approach them during appointments to minimize interference.
2) Using a dedicated research assistant to have greater coverage of clinics and flexibility in approaching patients.
3) Collecting multiple contact methods and an alternate contact to facilitate retention through regular reminders via phone, email, and in-person.
4) Carefully tracking patients in databases helped with retention rates averaging over 80% at follow-up timepoints up to a year later despite the challenges of this patient group.
This editorial discusses a study that uses survival modeling to predict the benefits of adjuvant chemoradiotherapy for patients with resected gallbladder cancer. The editorial makes three key points:
1) Computer modeling can help address gaps in clinical cancer research when randomized controlled trial data is limited, by using existing data to generate individualized survival predictions and treatment benefit estimates.
2) The gallbladder cancer study demonstrates how modeling can provide guidance for clinical decisions and research directions when high-quality evidence is lacking.
3) Models must be rigorously developed and validated, but can complement clinical trials by extending findings to new populations and longer time horizons not feasible in trials.
This document describes a study that aimed to create a predictive nomogram to help clinicians determine which patients with resected gallbladder cancer would benefit from adjuvant chemoradiotherapy (CRT). The study used a database of 1,137 patients from the SEER-Medicare database to develop several multivariate survival models. A lognormal survival model showed the best performance. From this model, researchers built a nomogram available online to provide individualized estimates of survival benefit from adjuvant CRT. The nomogram can predict that certain high-risk patients with T2 or N1 disease would gain a survival benefit from adjuvant CRT.
This case study describes the treatment of a 29-year-old man diagnosed with medulloblastoma, a rare pediatric brain tumor. He faced challenges due to being in the adolescent and young adult (AYA) population with limited access to insurance and care. Through multidisciplinary coordination between pediatric and adult specialists, he received aggressive treatment including surgery, radiation, and chemotherapy according to a pediatric protocol. While treatment caused morbidity, he remains disease-free one year later, demonstrating how comprehensive care can benefit AYAs despite the unique barriers they face.
This document describes the implementation of an Adolescent and Young Adult Oncology (AYAO) training program at Oregon Health & Science University (OHSU). The program includes two training pathways - a primary 4-year pathway following a combined Med-Peds residency, and an alternate supplemental 1-year pathway following a 3-year pediatric or medical hematology/oncology fellowship. The goal is to train oncologists in both pediatric and adult oncology to improve care, models, and outcomes for patients aged 15-39 with cancer. OHSU currently has two AYAO fellows, one in each pathway, gaining experience in both pediatric and adult oncology clinics and conducting AYA-focused clinical research. The training models
Knight Cancer Institute will host a seminar on November 15, 2011 titled "Autosomal Analog of X-Inactivation" presented by Dr. Alexander Gimelbrant from Dana-Farber Cancer Institute and Harvard Medical School. The seminar will discuss random monoallelic expression on autosomes, similar to X-inactivation, for genes coding cytokines, immunoglobulins, and olfactory receptors. The event will be held in the OHSU Main Hospital 8th Floor Conference Room B860 and is open to the public and provides continuing medical education credits.
The document announces a lecture titled "Childhood Cancer Research: 21st Century Science, 20th Century Clinical Trials" to be presented by Peter C. Adamson, MD on November 3, 2011 from 8:00-9:00am in the Marion Miller Auditorium on the 11th floor of Doernbecher Children's Hospital.
This document summarizes an upcoming seminar hosted by the Knight Cancer Institute at OHSU. The seminar will feature Dr. Ranadip Pal who will present on "Modeling Cancer Pathways: How Mathematical Modeling can Assist in Selecting & Predicting the Effectiveness of Targeted Drug Combinations." The seminar will take place on October 18, 2011 from 4:00-5:00pm in the OHSU Main Hospital 8th Floor Conference Room 8B60. The seminar series is designed to assist healthcare professionals and promote the integration of engineering and medicine in cancer treatment.
The 19th annual Harvey Baker Memorial Lecture will be held on Wednesday, October 19, 2011 at OHSU's Old Library auditorium. Dr. Scott Howard, director of clinical trials in international pediatric oncology at St. Jude Children's Hospital, will give a lecture titled "Childhood Cancer Care in Low Income Countries" from 7:00-8:30 PM. The lectureship honors Dr. Harvey Baker, the first formally trained surgical oncologist in Oregon who had a keen interest in cancer education.
The Knight Cancer Institute seminar series provides presentations by leading scientists on topics of fundamental science and translational research related to cancer. The seminars take place on Tuesdays from 4-5pm in the OHSU Main Hospital 8th floor conference room. The schedule lists seminar speakers from October 2011 through May 2012, including their institutional affiliations and topics. The seminars are open to physicians, nurses, researchers, and other healthcare professionals and offer continuing education credits.
Congestive Heart failure is caused by low cardiac output and high sympathetic discharge. Diuretics reduce preload, ACE inhibitors lower afterload, beta blockers reduce sympathetic activity, and digitalis has inotropic effects. Newer medications target vasodilation and myosin activation to improve heart efficiency while lowering energy requirements. Combination therapy, following an assessment of cardiac function and volume status, is the most effective strategy to heart failure care.
This document recognizes and honors individuals from the OHSU Knight Cancer Institute for their contributions in areas like clinical care, research, outreach, diagnostics, and informed consent. It provides photos and names of researchers, doctors, nurses, and staff being recognized for their work in areas such as breast cancer research and care, clinical scholars, phase I clinical trials, community outreach, prostate cancer research, diagnostic testing, and developing an informed consent model.
The document provides an agenda for OHSU PAIN Day 2012, an event taking place on February 28th from 12pm to 6pm at the Vey Conference Center at Doernbecher Children's Hospital. The agenda includes introductions, workshops on managing pain in different populations and facial pain, presentations on drug development and opioids for chronic pain, poster sessions, and a networking social hour. Registration is free online and continuing education credits will be provided.
This grant supports research using quantitative dual-energy CT (DECT) iodine measurements to evaluate treatment response in patients with liver metastases from colon cancer undergoing chemotherapy. DECT may allow earlier detection of treatment response compared to current size-based methods. The goal is to validate intralesional iodine concentration as a biomarker for predicting and monitoring response to anti-angiogenic chemotherapy. If successful, DECT iodine quantification could help personalize chemotherapy regimens and lead to improved outcomes for these patients.
A benefit event will be held on December 8th from 6:30-8:30pm at AVA Roasteria in Beaverton, Oregon to support patient services at the OHSU Knight Cancer Institute. Attendees can enjoy wine, hors d'oeuvres and music while learning how donations make a difference for cancer patients. A "snowball effect" fundraiser will also be held where purchasing gifts between $50-$1000 will help support wellness programs, art therapy, and patient assistance.
The Knight Cancer Institute Seminar Series will host Dr. Bradley Olwin from the University of Colorado, Boulder on December 13, 2011. Dr. Olwin will present on "The Role of the Niche in Self-Renewal & Transplantation of Muscle Stem Cells". The seminar will take place from 4:00-5:00pm in the OHSU Main Hospital 8th Floor Conference Room 8B60. The presentation will discuss the potential of muscle stem cell therapies and the mechanisms governing muscle stem cell self-renewal. The seminar is open to the public and provides continuing education credits for physicians.
Carolyn Blasdel is a research nurse at The Knight Cancer Institute. A patient submitted a letter praising Carolyn for her outstanding care and dedication. When the patient developed severe abdominal pain on a trip to Portland for a clinical trial, Carolyn dropped everything to meet and help the patient, correctly diagnosing acute pancreatitis. She stayed with the patient until evening and worked late into the night to prepare for the next day, showing continued support over following days. The patient said Carolyn is a huge asset to her care team and deserves recognition for her dedication to patients.
Sierra Romesburg from the Breast Center went above and beyond her normal duties to fill a gap when the center was without a nurse for six months. She teamed up with a registered nurse to take on nurse duties like calling patients to provide reassurance about their cancer diagnosis. Sierra is very knowledgeable about breast cancer treatments from independently researching the topic. She strives to educate patients on all treatment options available and never refuses patient requests, going to great lengths to fulfill them. Her dedication and willingness to take on extra work impress her colleagues.
Survival rates for adolescents and young adults (ages 15-39) with cancer have lagged behind progress made in children and older adults over the past 20 years. While significant strides have been made recently, more work is still needed. Key challenges contributing to lower survival in this age group include differences in cancer biology, lack of clinical trial participation, health insurance barriers, and lack of psychosocial support systems tailored for their unique needs and life stages. The oncology community has started to address these issues through greater research focus on this population, improved guidelines, and programs dedicated to their care. However, broad changes are still required to improve outcomes for adolescents and young adults with cancer.
Imjai Chitapanarux is a radiation oncologist and chair of the Division of Therapeutic Radiology and Oncology at Chiang Mai University's Faculty of Medicine in Thailand. He holds an MD and leads the division of radiation oncology and oncology at one of Thailand's top medical schools.
This project describes methods for recruiting and retaining adolescent and young adult (AYA) oncology patients in psychosocial research studies at a single institution. Key methods included:
1) Monitoring clinic schedules and patient wards daily to identify eligible patients and approach them during appointments to minimize interference.
2) Using a dedicated research assistant to have greater coverage of clinics and flexibility in approaching patients.
3) Collecting multiple contact methods and an alternate contact to facilitate retention through regular reminders via phone, email, and in-person.
4) Carefully tracking patients in databases helped with retention rates averaging over 80% at follow-up timepoints up to a year later despite the challenges of this patient group.
This editorial discusses a study that uses survival modeling to predict the benefits of adjuvant chemoradiotherapy for patients with resected gallbladder cancer. The editorial makes three key points:
1) Computer modeling can help address gaps in clinical cancer research when randomized controlled trial data is limited, by using existing data to generate individualized survival predictions and treatment benefit estimates.
2) The gallbladder cancer study demonstrates how modeling can provide guidance for clinical decisions and research directions when high-quality evidence is lacking.
3) Models must be rigorously developed and validated, but can complement clinical trials by extending findings to new populations and longer time horizons not feasible in trials.
This document describes a study that aimed to create a predictive nomogram to help clinicians determine which patients with resected gallbladder cancer would benefit from adjuvant chemoradiotherapy (CRT). The study used a database of 1,137 patients from the SEER-Medicare database to develop several multivariate survival models. A lognormal survival model showed the best performance. From this model, researchers built a nomogram available online to provide individualized estimates of survival benefit from adjuvant CRT. The nomogram can predict that certain high-risk patients with T2 or N1 disease would gain a survival benefit from adjuvant CRT.
This case study describes the treatment of a 29-year-old man diagnosed with medulloblastoma, a rare pediatric brain tumor. He faced challenges due to being in the adolescent and young adult (AYA) population with limited access to insurance and care. Through multidisciplinary coordination between pediatric and adult specialists, he received aggressive treatment including surgery, radiation, and chemotherapy according to a pediatric protocol. While treatment caused morbidity, he remains disease-free one year later, demonstrating how comprehensive care can benefit AYAs despite the unique barriers they face.
This document describes the implementation of an Adolescent and Young Adult Oncology (AYAO) training program at Oregon Health & Science University (OHSU). The program includes two training pathways - a primary 4-year pathway following a combined Med-Peds residency, and an alternate supplemental 1-year pathway following a 3-year pediatric or medical hematology/oncology fellowship. The goal is to train oncologists in both pediatric and adult oncology to improve care, models, and outcomes for patients aged 15-39 with cancer. OHSU currently has two AYAO fellows, one in each pathway, gaining experience in both pediatric and adult oncology clinics and conducting AYA-focused clinical research. The training models
Knight Cancer Institute will host a seminar on November 15, 2011 titled "Autosomal Analog of X-Inactivation" presented by Dr. Alexander Gimelbrant from Dana-Farber Cancer Institute and Harvard Medical School. The seminar will discuss random monoallelic expression on autosomes, similar to X-inactivation, for genes coding cytokines, immunoglobulins, and olfactory receptors. The event will be held in the OHSU Main Hospital 8th Floor Conference Room B860 and is open to the public and provides continuing medical education credits.
The document announces a lecture titled "Childhood Cancer Research: 21st Century Science, 20th Century Clinical Trials" to be presented by Peter C. Adamson, MD on November 3, 2011 from 8:00-9:00am in the Marion Miller Auditorium on the 11th floor of Doernbecher Children's Hospital.
This document summarizes an upcoming seminar hosted by the Knight Cancer Institute at OHSU. The seminar will feature Dr. Ranadip Pal who will present on "Modeling Cancer Pathways: How Mathematical Modeling can Assist in Selecting & Predicting the Effectiveness of Targeted Drug Combinations." The seminar will take place on October 18, 2011 from 4:00-5:00pm in the OHSU Main Hospital 8th Floor Conference Room 8B60. The seminar series is designed to assist healthcare professionals and promote the integration of engineering and medicine in cancer treatment.
The 19th annual Harvey Baker Memorial Lecture will be held on Wednesday, October 19, 2011 at OHSU's Old Library auditorium. Dr. Scott Howard, director of clinical trials in international pediatric oncology at St. Jude Children's Hospital, will give a lecture titled "Childhood Cancer Care in Low Income Countries" from 7:00-8:30 PM. The lectureship honors Dr. Harvey Baker, the first formally trained surgical oncologist in Oregon who had a keen interest in cancer education.
The Knight Cancer Institute seminar series provides presentations by leading scientists on topics of fundamental science and translational research related to cancer. The seminars take place on Tuesdays from 4-5pm in the OHSU Main Hospital 8th floor conference room. The schedule lists seminar speakers from October 2011 through May 2012, including their institutional affiliations and topics. The seminars are open to physicians, nurses, researchers, and other healthcare professionals and offer continuing education credits.
Congestive Heart failure is caused by low cardiac output and high sympathetic discharge. Diuretics reduce preload, ACE inhibitors lower afterload, beta blockers reduce sympathetic activity, and digitalis has inotropic effects. Newer medications target vasodilation and myosin activation to improve heart efficiency while lowering energy requirements. Combination therapy, following an assessment of cardiac function and volume status, is the most effective strategy to heart failure care.
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...Donc Test
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Jim Jacob Roy
In this presentation , SBP ( spontaneous bacterial peritonitis ) , which is a common complication in patients with cirrhosis and ascites is described in detail.
The reference for this presentation is Sleisenger and Fordtran's Gastrointestinal and Liver Disease Textbook ( 11th edition ).
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
- Video recording of this lecture in English language: https://youtu.be/RvdYsTzgQq8
- Video recording of this lecture in Arabic language: https://youtu.be/ECILGWtgZko
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
1. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
BRAIN TUMORS
Ependymoma PETEY 774- II A randomized, Phase II study of single agent Kellie Nazemi, MD
205 Erlotinib versus oral etoposide in patients with 503-494-0829
recurrent or refractory pediatric Ependymoma
(OSI ) Rae Acosta RN, CPON
503-418-4467
Recurrent Low-Grade RAD001 II A phase II study of RAD001 (Everolimus) for Kellie Nazemi, MD
Gliomas children with chemotherapy and/or Radiation 503-494-0829
(POETIC) refractory progressive or recurrent low grade
gliomas Rae Acosta RN, CPON
503-418-4467
High Grade Gliomas ACNS0621 II Cilengitide (EMD 12194) in recurrent or Kellie Nazemi, MD
progressive and refractory childhood high grade 503-494-0829
(COG) Glioma
Rae Acosta RN, CPON
503-418-4467
Childhood ACNS0821 II Temozolomide with Irinotecan versus Kellie Nazemi, MD
Medulloblastoma / CNS Temozolomide plus Bevacizumab for refractory/ 503-494-0829
PNET (COG) Recurrent Medulloblastoma/CNS PNET of child-
hood, a COG Phase II randomized trial Rae Acosta RN, CPON
503-418-4467
Newly diagnosed High ACNS0822 I/II A randomized Phase I/II study of Vorinostat Kellie Nazemi, MD
Grade Gliomas And local irradiation OR Temozolomide and 503-494-0829
(COG) Local irradiation OR Bevacizumab and local
Irradiation followed by maintenance Bevacizu- Rae Acosta RN, CPON
mab and Temozolomide in children with newly 503-418-4467
Diagnosed High grade gliomas.
Newly diagnosed diffuse ACNS0927 I/II A phase I/II study of Suberoylanilide Hydrox- Kellie Nazemi, MD
Intrinsic Pontine Glioma amic 503-494-0829
(DIPG) (COG) Acid (SAHA,Vorinostat) and local irradiation,
Followed by maintenance SAHA in children with Rae Acosta RN, CPON
Newly diagnosed DIPG 503-418-4467
2. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page 2
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
Solid Tumors
Solid Tumors ADVL0813 I A Phase I study of IMC-A12 (anti-insulin-like Suman Malempati, MD
Growth factor-1 Receptor Monoclonal antibody)
(COG) in combination with CCI-779 (temsirolimus) in Rae Acosta RN, CPON
Pediatric patients with recurrent or refractory 503-418-4467
solid tumors
Solid Tumors ADVL0815 I A phase I study of Pazopanib as a single agent for Suman Malempati, MD
children with refractory solid tumors
(COG) Rae Acosta RN, CPON
503-418-4467
Solid Tumors or ADVL0816 I A phase I study of Obatoclax (Pan Anit- Suman Malempati, MD
Leukemia Apoptotic BCL-2 family small molecule inhibi-
(COG) tor), in combination with Vincristine/ Rae Acosta RN, CPON
Doxorubicin/ Dexrazoxane, in children with 503-418-4467
Relapsed/Refractory solid tumors or Leukemia
Solid Tumors ADVL0821 II A phase II study of IMC-A12 in children with Suman Malempati, MD
Relapsed or refractory solid tumors
(COG) Rae Acosta RN, CPON
503-418-4467
Solid Tumors and ALCL ADVL0912 I/II PF-02341066 for ALK and C-Met for patients Suman Malempati, MD
with relapsed or refractory solid tumors and
(COG) ALCL Rae Acosta RN, CPON
503-418-4467
Recurrent or Refractory ADVL1013 I A Phase I study of MK-2206, an AKT inhibitor Suman Malempati, MD
Solid Tumors or In Pediatric patients with recurrent or refractory
Leukemia (COG) Solid tumors or Leukemia Rae Acosta RN, CPON
503-418-4467
3. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page 3
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
Solid Tumors
Solid Tumors ADVL1011 I A phase I study of JAK Inhibition in children Suman Malempati, MD
With Relapsed or Refractory Solid Tumors,
(COG) Rae Acosta RN, CPON
503-418-4467
Solid Tumors ADVL0918 I A phase I study of of Temsirolimus in combina- Suman Malempati, MD
tion with Irinotecan and Temozolomide in
(COG) children , adolescents and young adults with Rae Acosta RN, CPON
relapsed or refractory solid tumors 503-418-4467
Solid Tumors AMG954- I Suman Malempati, MD
20050252 Panitumumab in children with solid tumors
Rae Acosta RN, CPON
(Amgen) 503-418-4467
Solid Tumors ADVL0413 I A phase I study of the Raf Kinase and Receptor Suman Malempati, MD
Tyrosine Kinase Inhibitor Sorafenib in children
(COG) With refractory solid tumors or refractory Rae Acosta RN, CPON
Leukemia's 503-418-4467
Solid Tumors ADVL0612 I A phase I study of Sunitinib and oral multi- Suman Malempati, MD
targeted tyrosine kinase inhibitor, in children with
(COG) refractory solid tumors Rae Acosta RN, CPON
503-418-4467
4. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page 4
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
LEUKEMIA STUDIES
Philadelphia AALL0622 II Intensified Tyrosine Kinase Inhibitor Therapy Bill Chang, MD
Chromosome + ALL (Dasatinib) in Philadelphia Chromosome + ALL
(COG) Rae Acosta RN, CPON
503-418-4467
Relapsed KITE 2046 I/II Bendamustine (Treanda) in relapsed pediatric Bill Chang, MD
Acute Leukemia ALL
(Cephalon, Inc) Rae Acosta RN, CPON
503-418-4467
Pediatric AML E7373-G000- Pilot Pre-Induction Decitabine Priming for Pediatric Linda Stork, MD
202 AML subjects
Rae Acosta RN, CPON
(Eisai, Inc) 503-418-4467
Leukemia's and ADVL1011 I A phase I study of JAK Inhibition in children Suman Malempati, MD
Myeloproliferative With Relapsed or Refractory Solid Tumors,
Neoplasm's, (COG) Rae Acosta RN, CPON
Solid Tumors 503-418-4467
Ph+ Leukemia CA180226 II Dasatinib in Children and Adolescents with Ph+ Linda Stork, MD
Leukemia with resistance or Intolerance to
(BMS) Imatinib Rae Acosta RN, CPON
503-418-4467
Recurrent or Refractory ADVL1013 I A Phase I study of MK-2206, an AKT inhibitor Suman Malempati, MD
Solid Tumors or In Pediatric patients with recurrent or refractory
Leukemia (COG) Solid tumors or Leukemia Rae Acosta RN, CPON
503-418-4467
5. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page 5
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
LEUKEMIA STUDIES
Solid Tumors or ADVL0816 I A phase I study of Obatoclax (Pan Anit- Suman Malempati, MD
Leukemia Apoptotic BCL-2 family small molecule inhibi-
(COG) tor), in combination with Vincristine/ Rae Acosta RN, CPON
Doxorubicin/ Dexrazoxane, in children with 503-418-4467
Relapsed/Refractory solid tumors or Leukemia
Solid Tumors or ADVL0413 I A phase I study of the Raf Kinase and Receptor Suman Malempati, MD
Refractory Leukemia Tyrosine Kinase Inhibitor Sorafenib in children
(COG) With refractory solid tumors or refractory Rae Acosta RN, CPON
(AML and FLT3-ITD Leukemia's 503-418-4467
mutation)
CD-22 + Leukemia ADVL04P2 I/II A phase I/II pilot study of Chemoimmunotherapy Suman Malempati, MD
With Epratuzumab for children with Relapsed
(COG) CD-22 + ALL Rae Acosta RN, CPON
503-418-4467
Rhabdomyosarcoma Studies
High Risk ARST08P1 Pilot A pilot study to evaluate novel agents Suman Malempati, MD
Rhabdomyocarcoma (Temozolomide and Cixutumumab) in
(COG) combination with intensive multi-agent interval Rae Acosta RN, CPON
Compressed therapy for patients with high risk 503-418-4467
Rhabdomyosarcoma
Rhabdomyosarcoma ARST0921 II A randomized Phase II trial of Bevacizumab Suman Malempati, MD
(Avastin) and Temsirolimus (Torisol) in
(COG) Combination with IV Vinorelbine and Rae Acosta RN, CPON
Cyclophosphamide in subjects with recurrent or 503-418-4467
Refractory Rhabdomyosarcoma
6. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page 6
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
Bonemarrow and stem cell transplant protocols
Severe aplastic anemia BMT CTN I/II Fludarabine-based conditioning for allogeneic Gabrielle Meyers, MD
0301 marrow transplantation from HLA compatible 503-494-1551
unrelated donors in severe aplastic anemia
(BMT CTN) Allison Moore RN
503-418-5341
Hodgkins disease and BUMELTT II A phase II study to evaluate the safety and Richard Maziarz, MD
non-hodgkins lymphoma efficacy of IV busulfan, melphalan, and thiotepa 503-494-1551
(OHSU) (BuMelTT) regimen followed by autologous
PBSC infusion for patients with hodgkins disease Allison Moore RN
and non-hodgkins lymphoma 503-418-5341l
Hematologic BU/FLU/TBI I/II A Phase I/Il non-myeloablative allogenic Richard Maziarz, MD
malignancies Hematopoietic stem cell transplant for the 503-494-1551
(OHSU) Treatment of patients with hematologic malig-
nancies using busulfan, fludarbine and total body Allison Moore RN
irradiation 503-418-5341
Hematologic T2008-005 I Phase I feasibility study of clofarabine and low Eneida Nemecek, MD
malignancies dose total body irradiation (TBI) as a non- 503-494-0829
(TACL) Myeloblative preperative regimen for stem cell
Multicenter transplant (SCT) for hematologic malignancies Allison Moore RN
503-418-5341
Ph+ Leukemia FHCRC 2223 I/II A multicenter phase I/II study of the prophylactic Michael Mauro, MD
inhibition of BCR-ABL tyrosine kinase by 503-494-1551
(FHCRC) Tasigna (Nilotinib) after HSCT for Ph+ leukemia
Allison Moore RN
503-418-5341
Interstitial pneumonia ASCT0521 II Soluble tumor necrosis factor: Enbrel Bill Chang, MD
Syndrome following (Etanercept) for the treatment of acute non- 503-494-0829
Allogeneic stem cell (COG) infectious pulmonary dysfunction (interstitial
transplant pneumonia syndrome) following allogeneic stem Allison Moore RN
cell transplantation. 503-418-5341